Subscribe
designer491-3
designer491 / iStockphoto.com
3 December 2018Americas

GSK seeks to boost oncology repertoire with $5.1bn acquisition

GSK has agreed to buy US oncology company Tesaro for $5.1 billion (£4 billion), in a move designed to strengthen its anti-cancer offering.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
GSK completes buyout of Novartis from joint venture
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.
Americas
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
6 February 2019   UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Big Pharma
Vaccines growth offsets Advair generic pain for GSK
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
GSK completes buyout of Novartis from joint venture
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.
Americas
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
6 February 2019   UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Big Pharma
Vaccines growth offsets Advair generic pain for GSK
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.

More on this story

Big Pharma
GSK completes buyout of Novartis from joint venture
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.
Americas
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
6 February 2019   UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Big Pharma
Vaccines growth offsets Advair generic pain for GSK
25 July 2019   Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages